Bilive^® ：

The first domestically developed combined hepatitis A and hepatitis B vaccine in China and the second such vaccine developed globally. It remains the only combined hepatitis A and hepatitis B vaccine currently available in China.

The bulk production process for hepatitis A component has been prequalified by the World Health Organization (WHO).

• Dual Protection with a Single Vaccination

An Important Contribution to Accelerate Hepatitis Elimination in China by 2030.

• Efficient Dual-Disease Protection

Provides simultaneous protection against two diseases through a streamlined vaccination approach, helping reduce the number of required doses and support vaccination uptake.

• Flexible Vaccination Schedules

Flexible dosing schedules are available to support different immunization needs.

Depending on immunization objectives and clinical recommendations, different dosing schedules may be applied.